首页> 外文期刊>Naunyn-Schmiedeberg's Archives of Pharmacology >Effects of new class III antiarrhythmic drug niferidil on electrical activity in murine ventricular myocardium and their ionic mechanisms
【24h】

Effects of new class III antiarrhythmic drug niferidil on electrical activity in murine ventricular myocardium and their ionic mechanisms

机译:新型III类抗心律不齐药物Niferidil对鼠心室心肌电活动的影响及其离子机制

获取原文
获取原文并翻译 | 示例
           

摘要

A new class III antiarrhythmic drug niferidil has been recently introduced as a highly effective therapy cure for cases of persistent atrial fibrillation, but ionic mechanisms of its action are still unknown. Effects of niferidil on action potential (AP) waveform and major ionic currents were studied in mouse ventricular myocardium. APs were recorded with glass microelectrodes in multicellular preparations of right ventricular wall. Whole-cell patch-clamp technique was used to measure K+, Ca2+, and Na+ currents in isolated mouse ventricular myocytes. While 10(-7) M niferidil failed to alter the AP configuration, 10(-6) M tended to prolong APs (by 12.05 +/- A 1.8 % at 50 % of repolarization) and 10(-5) M induced significant slowing of repolarization (32.1 +/- A 4.9 % at 50 % of repolarization). Among the potassium currents responsible for AP repolarization phase, I (K1) was found to be almost insensitive to niferidil. I (to) demonstrated low sensitivity to niferidil with IC50 = 2.03 x 10(-4) M. I (Kur), which was previously hypothesized to be the main target of the drug, was more sensitive with IC50 = 6 x 10(-5) M. However, sustained delayed rectifier potassium current I (ss) was inhibited with even lower IC50 = 2.8 x 10(-5) M. Therefore, suppression of I (ss) and, second, I (Kur) by niferidil seems to underlie the AP prolongation in mouse ventricular tissue. Niferidil also produced a modest decrease in I (CaL) peak amplitude (IC50a parts per thousand 10(-4) M), but failed to alter I (Na) significantly. Niferidil prolongs APs in mouse ventricular myocardium mainly by inhibiting I (ss) and I (Kur) K+ currents, but not exclusively I (Kur), as was proposed earlier. Further investigations are required to reveal the mechanisms of niferidil action in human myocardium, where I (Kr) is strongly expressed instead of I (ss).
机译:最近已经引入了一种新的III类抗心律不齐药物niferidil,作为治疗持续性心房颤动的一种有效疗法,但其作用的离子机制仍然未知。研究了尼菲地尔对小鼠心室心肌动作电位(AP)波形和主要离子电流的影响。用玻璃微电极在右心室壁的多细胞制剂中记录AP。全细胞膜片钳技术用于测量分离的小鼠心室肌细胞中的K +,Ca2 +和Na +电流。尽管10(-7)M niferidil不能改变AP结构,但10(-6)M会延长AP(在重新极化的50%时增加12.05 +/- A 1.8%),而10(-5)M则导致显着减慢复极化的百分比(复极化的50%时为32.1 +/- A 4.9%)。在负责AP重新极化阶段的钾电流中,I(K1)被发现对Niferidil几乎不敏感。我(对)证明对尼弗地尔的敏感性低,IC50 = 2.03 x 10(-4)M。以前被假定为药物主要靶点的我(库尔)对IC50 = 6 x 10(-)更敏感5)M。但是,甚至更低的IC50 = 2.8 x 10(-5)M,抑制了持续延迟的整流器钾电流I(ss)。因此,似乎被niferidil抑制了I(ss)和第二,I(Kur)。在小鼠心室组织中AP延长的基础。 Niferidil还使I(CaL)峰幅度(IC50a份每千10(-4)M)适度降低,但未能显着改变I(Na)。如前所述,Niferidil主要通过抑制I(ss)和I(Kur)K +电流延长小鼠心室AP的寿命,但不仅仅抑制I(Kur)电流。需要进一步的研究来揭示尼弗地尔在人心肌中的作用机制,其中强烈表达I(Kr)而不是I(ss)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号